Vandetanib is an orally bioavailable anilino-quinazoline that selectively blocks vascular endothelial growth factor receptor-2 kinase at nanomolar potency and also targets vascular endothelial growth factor receptor-3 and epidermal growth factor receptor, suppressing angiogenesis and tumor proliferation.
Usually ships within 24 hours.